Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Shanghai - Delayed Quote CNY

Shanghai Rendu Biotechnology Co., Ltd. (688193.SS)

38.00
+1.00
+(2.70%)
At close: 3:00:04 PM GMT+8
Loading Chart for 688193.SS
  • Previous Close 37.00
  • Open 37.19
  • Bid 38.00 x --
  • Ask 38.21 x --
  • Day's Range 36.71 - 38.24
  • 52 Week Range 23.00 - 50.30
  • Volume 518,286
  • Avg. Volume 355,995
  • Market Cap (intraday) 1.52B
  • Beta (5Y Monthly) 0.21
  • PE Ratio (TTM) --
  • EPS (TTM) -0.26
  • Earnings Date --
  • Forward Dividend & Yield 0.30 (0.81%)
  • Ex-Dividend Date Oct 30, 2024
  • 1y Target Est --

Shanghai Rendu Biotechnology Co., Ltd. engages in the development and promotion of RNA molecular diagnostic technology and products. The company offers products in the areas of reproductive health, respiratory diseases, enterovirus, food safety, and blood infectious diseases, as well as automatic nucleic acid detection and analysis system. The company was founded in 2007 and is based in Shanghai, China.

www.rdbio.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 688193.SS

View More

Performance Overview: 688193.SS

Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

688193.SS
6.29%
SSE Composite Index (000001.SS)
1.06%

1-Year Return

688193.SS
17.37%
SSE Composite Index (000001.SS)
5.58%

3-Year Return

688193.SS
24.87%
SSE Composite Index (000001.SS)
10.48%

5-Year Return

688193.SS
44.12%
SSE Composite Index (000001.SS)
15.22%

Compare To: 688193.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 688193.SS

View More

Valuation Measures

Annual
As of 4/30/2025
  • Market Cap

    1.48B

  • Enterprise Value

    712.38M

  • Trailing P/E

    68.52

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    8.32

  • Price/Book (mrq)

    1.62

  • Enterprise Value/Revenue

    4.11

  • Enterprise Value/EBITDA

    37.99

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -4.16%

  • Return on Assets (ttm)

    -0.74%

  • Return on Equity (ttm)

    -0.78%

  • Revenue (ttm)

    177.35M

  • Net Income Avi to Common (ttm)

    -7.38M

  • Diluted EPS (ttm)

    -0.26

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    677.85M

  • Total Debt/Equity (mrq)

    0.52%

  • Levered Free Cash Flow (ttm)

    -47.03k

Research Analysis: 688193.SS

View More

Company Insights: 688193.SS

Research Reports: 688193.SS

View More

People Also Watch